Nanoparticle-based prostate cancer-specific delivery approach and adenoviral approach to systemically deliver the AR siRNA expression particles documented a rapid xenograft tumor regression and eradication owing to robust cell death in vivo (16, 17). This evidence concerns the gene AR and prostate carcinoma.